Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.

Clinical features affecting survival in metastatic NSCLC treated with immunotherapy : A critical review of published data / A. Passaro, I. Attili, S. Morganti, E. Del Signore, L. Gianoncelli, G. Spitaleri, V. Stati, C. Catania, G. Curigliano, F. de Marinis. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 89(2020 Sep), pp. 102085.1-102085.10. [10.1016/j.ctrv.2020.102085]

Clinical features affecting survival in metastatic NSCLC treated with immunotherapy : A critical review of published data

S. Morganti;L. Gianoncelli;G. Curigliano
Conceptualization
;
2020

Abstract

Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.
Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic
Settore MED/06 - Oncologia Medica
22-lug-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Passaro and Curigliano CTR 2020.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 590.13 kB
Formato Adobe PDF
590.13 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824798
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 27
social impact